Hims vs MyStart Health

Choose hims if: You need extensive men's health platform addressing weight loss plus other conditions (erectile dysfunction, hair loss, mental health, skincare), want men's health medical team with expertise in testosterone, sexual function, male metabolic factors vs gender-neutral obesity treatment, value the longest-established telehealth platform (7+ years, millions served) for maximum treatment continuity confidence versus brand-new platform extreme risks (<1 year in), seek healthcare consolidation under single provider relationship managing multiple men's health dimensions, need medication flexibility (semaglutide AND tirzepatide when prescribed), prioritize treatment reliability and business sustainability over absolute minimum pricing, or recognize maturity worth premium over ultra-budget startup with questionable long-term viability.

Choose MyStart Health if: You prioritize absolute lowest GLP-1 pricing ($2,148-2,748/year, potentially $500-1,500+ savings) despite extreme risks, exclusively need weight loss without other men's health services, satisfied with semaglutide-only formulary without tirzepatide access, accept brand-new platform extreme risks (<1 year of history, pricing so aggressive the business model is questionable), extreme cost sensitivity drives decision-making over reliability or multi-category utility, willing to gamble on newest market entrant for maximum cost savings accepting catastrophic potential if platform fails mid-treatment, can tolerate potential service discontinuation or medication supply interruptions disrupting 12-18 month GLP-1 therapy, or make purchasing decisions based solely on lowest price regardless of startup failure risks.

Bottom line: hims and MyStart Health represent extreme opposite ends of telehealth spectrum - established wide-ranging multi-category platform vs brand-new ultra-budget medication-only specialist. hims operates as proven men's health consolidation (7+ years, millions served, public company) providing weight management integrated with erectile dysfunction, hair loss, mental health, skincare through men's health medical team at higher costs ($2,000-4,500+/year estimated). MyStart Health functions as newest market entrant (<1 year, zero validation) providing semaglutide-only medication with minimal consultations through ultra-aggressive pricing ($2,148-2,748/year) raising serious questions about whether the model holds. MyStart Health delivers dramatic cost savings (potentially $500-1,500+/year) but extreme risks: brand-new operations, untested business model, medication-only limitation, semaglutide-only formulary, gender-neutral treatment, zero multi-category utility. hims higher costs but comprehensive advantages: proven 7+ years operations providing treatment continuity confidence, men's health expertise, multi-category consolidation eliminating need for separate platforms (weight + ED + hair loss under single provider), medication flexibility, and a business that has already lasted. For men exclusively needing ultra-budget semaglutide accepting extreme startup risks and medication-only limitation, MyStart Health delivers lowest cost. For men valuing continuity, coordinated multi-health needs, or men's health specialization, hims' full approach and extensive track record justify higher costs. Rational decision-making favors hims despite premium - 7+ years proven operations, millions served, multi-category utility, men-specific expertise worth the investment over brand-new ultra-budget platform carrying significant failure risks potentially catastrophic mid-treatment.